AG
AXDX

Aperio Group’s Accelerate Diagnostics AXDX Stock Holding History

Aperio Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,073
Closed -$89K – 2342
2020
Q1 		$89K Buy
+1,073
New +$151K ﹤0.01% 2227
2019
Q3 		– Sell
-625
Closed -$143K – 2345
2019
Q2 		$143K Buy
+625
New +$122K ﹤0.01% 2289

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Aperio Group's AXDX Position: Q2 2020 in Review

Aperio Group sold out of Accelerate Diagnostics (AXDX) in Q2 2020, closing a stake of 1,073 shares — an estimated $89K sold.

Aperio Group first reported a position in AXDX in Q2 2019 and held it in 2 quarters. The position peaked at $143K in Q2 2019. 123 funds tracked by Wall St. Rank hold AXDX as of Q2 2020.

  • Aperio Group reported no remaining Accelerate Diagnostics position as of Q2 2020 after selling out during the quarter.
  • Aperio Group sold 1,073 Accelerate Diagnostics shares in Q2 2020, an estimated $89K.
  • Aperio Group first reported a position in Accelerate Diagnostics in Q2 2019 and held it in 2 quarters.
  • Aperio Group's Accelerate Diagnostics position peaked at $143K in Q2 2019.
  • 123 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2020.

Based on Aperio Group's 13F filing for Q2 2020, filed 13 Aug 2020.